Biotech Values

[DewDiligence]

>vrtx would be a stupid company if they weren't hard at work on improving upon 950. For starters hopefully its a better dosing regimen.<

Naturally, they have a follow-on compound. My question was about timing of the announcement of this compound a few days before AASLD. A cynic might think the timing was intended to prepare the investment community for less than stellar Telaprevir presentations next week.